Search company, investor...



Unattributed VC - II | Alive

Total Raised


Last Raised

$7.26M | 1 yr ago

About Oncorena

Oncorena develops a drug based on the natural substance orellanine, a highly kidney selective toxin from certain mushrooms. The therapeutic concept is to treat patients with metastasized renal clear cell cancer in dialysis with orellanine.

Headquarters Location

Kullagatan 8

Helsingborg, 252 20,


Missing: Oncorena's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Oncorena's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Oncorena

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oncorena is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Oncorena Patents

Oncorena has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Kidney cancer, Polysaccharides, Oncology, Cancer treatments, Dermal and subcutaneous growths


Application Date


Grant Date



Related Topics

Kidney cancer, Polysaccharides, Oncology, Cancer treatments, Dermal and subcutaneous growths



Latest Oncorena News

Yerxa leaving Foundation Fighting Blindness to become Opus’ permanent CEO

Jun 22, 2022

Yerxa leaving Foundation Fighting Blindness to become Opus’ permanent CEO  Plus Biden to nominate Arati Prabhakar as director of OSTP, and updates from Oncorena, Panorama, Indivior, Prolacta and more By Richard Guy, Biopharma Analyst and Gunjan Ohri, Data Content Analyst June 22, 2022 12:49 AM UTC Foundation Fighting Blindness CEO Ben Yerxa will become permanent CEO at Opus Genetics Inc. — the first company to spin out from the foundation and its venture arm, the Retinal Degeneration ... Access this Article

Oncorena Frequently Asked Questions (FAQ)

  • Where is Oncorena's headquarters?

    Oncorena's headquarters is located at Kullagatan 8, Helsingborg.

  • What is Oncorena's latest funding round?

    Oncorena's latest funding round is Unattributed VC - II.

  • How much did Oncorena raise?

    Oncorena raised a total of $8.85M.

  • Who are the investors of Oncorena?

    Investors of Oncorena include HealthCap Venture Capital, Linc Invest, FSG Fond and Aqilion.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.